Co-Founder of Prismic Pharmaceuticals and Founder of Phytoquest Join Forces in Primary Medicines Ltd

Primary Medicines will investigate a widespread but rarely noticed class of compounds called iminosugars. Sugars are crucially important to how the body functions and iminosugars seem able via several mechanisms to regulate and correct aberrations which occur in carbohydrates in disease states. The iminosugars are present in some common fruits and vegetables with anecdotal health benefits but the therapeutic potential in Metabolic syndrome is barely studied.

Danilo Casadei Massari, Co-Founder of Prismic Pharmaceuticals and CEO of ExPharma Limited, and Dr. Robert Nash, Founder of Phytoquest have joined forces to establish a new company, Primary Medicines Limited. The new company is based in London and will focus on the Development of novel products for the management of Metabolic syndrome and glucose imbalance. 

Metabolic syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease. 

Metabolic syndrome, also named Dysmetabolic syndrome, Hypertriglyceridemic waist, Insulin resistance syndrome, Obesity syndrome and Syndrome X, is becoming more common due to a rise in obesity rates among adults. In the future, metabolic syndrome may overtake smoking as the leading risk factor for heart disease.

Whilst it is possible to prevent or delay Metabolic syndrome, mainly with lifestyle changes, a healthy lifestyle is a lifelong commitment. Successfully controlling Metabolic syndrome could also benefit from specific nutritional supplementation. 

Primary Medicines Limited aims at exploring the potential of a widespread but rarely noticed class of compounds called iminosugars. The iminosugars are present in some common fruits and vegetable with anecdotal health benefits but the therapeutic potential is barely studied due to the specialist skills needed to synthesise or to isolate and identify them. 

Dr. Robert Nash says sugars are crucially important to how the body functions and iminosugars seem able via several mechanisms to regulate and correct aberrations which occur in carbohydrates in disease states.

Danilo Casadei Massari believes that the first iminosugar-based  product could be on the market no later than Q4 2017 and offer a novel and complementary opportunity to current management of Metabolic syndrome. 

Primary Medicines Ltd is a company registered in the UK with offices in 21 Effie Road, Fulham Broadway London SW61EN. For info contact Phone: +44 (0)2073852005, E-Mail: conciergecasadeimassari@gmail.com


Categories: Research and Development, Pharmaceuticals and Biotech, Healthcare and Medical Informatics

Tags: Danilo Casadei Massari, Expharma Limited, iminosugars, Metabolic syndrome, Phytoquest, Prismic Pharmaceuticals, Robert Nash